We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.
Supported by our strong cash balance, we are convinced that the potential of our target discovery platform, our drug development capabilities, and the strength of our teams position us well for future growth.
Onno van de Stolpe, CEO
Following the strategic exercise announced earlier this year, we are focused on advancing our refocused pipeline and implementing our savings program, while delivering on the commercial launch of Jyseleca in Europe.
Bart Filius, President & COO
